Exabis Library
Welcome to the e-CCO Library!
OP34: VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis
2019
ECCO '19 Copenhagen
Thursday, 28 February 2019, 8:13 AM
OP34: Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in Inflammatory Bowel Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
OP34: Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in Inflammatory Bowel Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP35 Treatment outcomes of inflammatory bowel disease in the biological era—a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP35: Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trial
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP35: Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trial
2021
ECCO'21 Virtual
Friday, 1 October 2021, 12:41 PM
OP35: Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
OP35: Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP35: Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
OP35: Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP35: Endoscopic and Deep Remission at 1 Year Prevents Disease Progression in Early Crohn’s Disease: Long-Term Data from CALM
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
OP35: Natural history of anal ulcerations in pediatric-onset Crohn's Disease: A population-based study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP35: Treatment outcomes of Inflammatory Bowel Disease in the biological era – A nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
OP35: Treatment outcomes of Inflammatory Bowel Disease in the biological era – A nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP36 Investigating the role of bioactives produced by gut bacteria to modulate immune response in inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP36: A colonic gene expression signature predicts non-response to anti-inflammatory therapies in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP36: Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP36: Investigating the role of bioactives produced by gut bacteria to modulate immune response in Inflammatory Bowel Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
OP36: Investigating the role of bioactives produced by gut bacteria to modulate immune response in Inflammatory Bowel Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP36: Real-world evidence on comparative effectiveness of Ustekinumab vs anti-TNF in Crohn's disease with propensity score adjustment: two-year maintenance phase results from the prospective observational RUN-CD study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM